Repaglinide
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA), specifically DLA Troop Support, is planning to issue a Presolicitation for a DoD-only national requirements contract for Repaglinide Tablets. This will be an unrestricted and fully competitive acquisition to establish a national supply source for the Department of Defense through DLA prime vendor programs. The projected solicitation date is September 2020.
Scope of Work
The requirement is for Repaglinide in 0.5MG, 1MG, and 2MG dosages, packaged in 100-count bottles. This contract will provide these items for purchase by the Department of Defense only. Annual usage estimates will be detailed in the forthcoming solicitation's Schedule of Supplies.
Contract & Timeline
- Type: Firm-Fixed Price, Requirements Type Contract
- Duration: One-year base period with four one-year options
- Set-Aside: Unrestricted and Fully Competitive
- Projected Solicitation Date: September 2020 (DLA reserves the right to issue before or after)
- Published: August 25, 2020
Additional Notes
This acquisition is for a commercial item and will be solicited using FAR Part 12. All sources may submit a proposal. The solicitation will be posted on the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Beta.Sam.Gov at https://beta.sam.gov. Interested parties should contact Phyllis Daraio at Phyllis.Daraio@dla.mil or 215-737-7941 for questions and are advised to set up automated notifications for updates.